[KO Validated] Anti-NSDHL Rabbit Polyclonal Antibody for WB, IHC-P, IF/ICC, ELISA - Q15738

Core Product Specifications and Parameters

Biological Background: NSDHL Function and Localization

• NSDHL (Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating), also designated H105E3, XAP104, SDR31E1, or HL, is an enzyme encoded by the NSDHL gene in humans.
• It catalyzes the NAD(P)(+)-dependent oxidative decarboxylation of the C4 methyl groups of 4-alpha-carboxysterols, a critical step in post-squalene cholesterol biosynthesis (By similarity).
• NSDHL additionally contributes to the regulation of endocytic trafficking of the epidermal growth factor receptor (EGFR) (By similarity).
• The protein belongs to the 3-beta-hydroxysteroid dehydrogenase/isomerase family and possesses short-chain dehydrogenase/reductase (SDR) domains; it is classified as an oxidoreductase utilizing NAD as a cofactor.
• Subcellularly, NSDHL localizes to the endoplasmic reticulum membrane and lipid droplets, consistent with its central role in sterol metabolism.
• It exhibits broad tissue expression, with detection reported in brain, heart, liver, lung, kidney, skin, and placenta.
• Post-translational modifications include acetylation and phosphorylation, which may modulate enzyme activity or interactions.
• Mutations in NSDHL are linked to CHILD syndrome (congenital hemidysplasia with ichthyosiform erythroderma and limb defects) and X-linked intellectual disability, underscoring its significance in lipid-related developmental disorders.

Experimental Guidance and Technical Tips

• The immunogen spans amino acids 1–240 of human NSDHL, a region containing conserved catalytic domains; this design may ensure broad recognition across species but always confirm sequence homology if working with non-listed organisms.
• For Western blotting, consider using a positive control such as lysate from HeLa, HepG2, or mouse liver tissue; the predicted molecular weight is approximately 42 kDa, though post-translational modifications may cause slight shifts.
• In immunohistochemistry (paraffin sections) and immunofluorescence, validate the antibody in tissues known to express NSDHL (e.g., skin, placenta) and optimize antigen retrieval conditions.
• Due to the polyclonal nature, background may vary between lots; inclusion of appropriate negative controls (KO lysates or blocking peptides) is recommended to assess specificity.
• For ELISA applications, pairing this antibody with a capture antibody targeting a distinct NSDHL epitope can enhance assay sensitivity; preliminary titration is advised.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive sourcing partner for IVD raw materials, supporting manufacturers, laboratories, and research institutes in developing diagnostic assays targeting cholesterol metabolism and related disorders. This NSDHL antibody complements our portfolio of validated antibody pairs, optimized polyclonals, and bulk ancillary reagents for biomarker detection, enzyme studies, and rare target material supply. Whether you require single reagents or fully integrated sourcing solutions, our team bridges the gap from concept to clinic, helping streamline your diagnostic pipeline with reliable raw material access.